Russian pharmacovigilance: ways to improve efficiency

Abstract

The paper presents the results of a survey of pharmacovigilance specialists’ awareness of the regulation of reporting on adverse drug reactions, self-assessment of their competencies and readiness for distance learning, creation of a generalized portrait of a pharmacovigilance specialist to create mechanisms for improving pharmacovigilance activities, and continuing education of pharmacovigilance specialists. The results of the correlation analysis of the knowledge of pharmacovigilance specialists with their self-assessment of their position are reflected. Information-analytical and sociological (survey) methods and descriptive statistics were used. A questionnaire consisting of 31 items was developed for the survey. The first part of the questionnaire consisted of general questions, such as on education, work experience in the pharmaceutical field and pharmacovigilance, and position held. The second part focused on the structure of pharmacovigilance in the organization of holders of the registration certificate. The third part consisted of 17 items aimed at identifying the level of knowledge concerning the immediate daily activities in pharmacovigilance and knowledge of the legislative framework. The final element was a question about the attitude to distance learning. Specialists working in the field of pharmacovigilance at enterprises and persons authorized for pharmacovigilance objectively assessed their practical knowledge and skills in the field of drug safety. Moreover, 42 (72%) respondents believe that they do not need to update their knowledge on pharmacovigilance, whereas 51 (87%) people successfully passed the proposed survey on knowledge of current legislation. Employees of senior positions showed higher knowledge in the field of pharmacovigilance. Specialists and senior pharmacovigilance specialists need to increase their level of professional knowledge, and they are aware of the need for further training.

Keywords

holders of the registration certificate / safety of medicines / adverse reactions / continuing education / distance learning / authorized person for pharmacovigilance / pharmacovigilance

References

[1] Pires C. A systematic review on learning outcomes of pharmacovigilance issues: Undergraduates of pharmacy. Int J Educ Res. 2021;109:101845. DOI: 10.1016/j.ijer.2021.101845

[2] Pires C. A systematic review on learning outcomes of pharmacovigilance issues: Undergraduates of pharmacy // Int J Educ Res. 2021. Vol. 109. ID 101845. DOI: 10.1016/j.ijer.2021.101845

[3] Ibrahim H, Abdo A, El Kerdawy AM, Eldin AS. Signal Detection in Pharmacovigilance: A Review of Informatics-driven Approaches for the Discovery of Drug-Drug Interaction Signals in Different Data Sources. Artificial Intelligence in the Life Sciences. 2021;1:100005. DOI: 10.1016/j.ailsci.2021.100005

[4] Ibrahim H., Abdo A., El Kerdawy A.M., Eldin A.S. Signal Detection in Pharmacovigilance: A Review of Informatics-driven Approaches for the Discovery of Drug-Drug Interaction Signals in Different Data Sources // Artificial Intelligence in the Life Sciences. 2021. Vol. 1. ID 100005. DOI: 10.1016/j.ailsci.2021.100005

[5] Vilar S, Friedman C, Hripcsak G. Detection of drug-drug interactions through data mining studies using clinical sources, scientific literature and social media. Brief Bioinform. 2018;19(5): 863–877. DOI: 10.1093/bib/bbx010

[6] Vilar S., Friedman C., Hripcsak G. Detection of drug-drug interactions through data mining studies using clinical sources, scientific literature and social media // Brief Bioinform. 2018. Vol. 19. No. 5. P. 863–877. DOI: 10.1093/bib/bbx010

[7] Lee CY, Phoebe Chen Y-P. Prediction of drug adverse events using deep learning in pharmaceutical discovery. Brief Bioinform. 2021;22(2):1884–1901. DOI: 10.1093/bib/bbaa040

[8] Lee C.Y., Phoebe Chen Y.-P. Prediction of drug adverse events using deep learning in pharmaceutical discovery // Brief Bioinform. 2021. Vol. 22. No. 2. P. 1884–1901. DOI: 10.1093/bib/bbaa040

[9] Ward IR, Wang L, Lu J, et al. Explainable artificial intelligence for pharmacovigilance: What features are important when predicting adverse outcomes? Comput Methods Programs Biomed. 2021;212:106415. DOI: 10.1016/j.cmpb.2021.106415

[10] Ward I.R., Wang L., Lu J., et al. Explainable artificial intelligence for pharmacovigilance: What features are important when predicting adverse outcomes? // Comput Methods Programs Biomed. 2021. Vol. 212. ID 106415. DOI: 10.1016/j.cmpb.2021.106415

[11] Norén GN, Meldau E-L, Chandler RE. Consensus clustering for case series identification and adverse event profiles in pharmacovigilance. Artificial Intelligence in Medicine. 2021;122:102199. DOI: 10.1016/j.artmed.2021.102199

[12] Norén G.N., Meldau E.-L., Chandler R.E. Consensus clustering for case series identification and adverse event profiles in pharmacovigilance // Artificial Intelligence in Medicine. 2021. Vol. 122. ID 102199. DOI: 10.1016/j.artmed.2021.102199

[13] Tissot M, Valnet-Rabier M-B, Stalder T, et al. Epidemiology and economic burden of “serious” adverse drug reactions: Real-world evidence research based on pharmacovigilance data. Therapies. 2022. [In Press]. DOI: 10.1016/j.therap.2021.12.007

[14] Tissot M., Valnet-Rabier M.-B., Stalder T., et al. Epidemiology and economic burden of “serious” adverse drug reactions: Real-world evidence research based on pharmacovigilance data // Therapies. 2022. [In Press]. DOI: 10.1016/j.therap.2021.12.007

[15] Peyvandi F, Garagiola I, Mannuccio-Mannucci P. Post-authorization pharmacovigilance for hemophilia in Europe and the USA: Independence and transparency are keys. Blood Rev. 2021;49:100828. DOI: 10.1016/j.blre.2021.100828

[16] Peyvandi F., Garagiola I., Mannuccio-Mannucci P. Post-authorization pharmacovigilance for hemophilia in Europe and the USA: Independence and transparency are keys // Blood Rev. 2021. Vol. 49. ID 100828. DOI: 10.1016/j.blre.2021.100828

[17] Tyagi S. Global research output in ‘pharmacovigilance’ during 2010–2020. Therapies. 2021. [In Press]. DOI: 10.1016/j.therap.2021.11.011

[18] Tyagi S. Global research output in ‘pharmacovigilance’ during 2010–2020 // Therapies. 2021. [In Press]. DOI: 10.1016/j.therap.2021.11.011

[19] Mouffak A, Lepelley M, Revol B, et al. High prevalence of spin was found in pharmacovigilance studies using disproportionality analyses to detect safety signals: a meta-epidemiological study. J Clin Epidemiol. 2021;138:73–79. DOI: 10.1016/j.jclinepi.2021.06.022

[20] Mouffak A., Lepelley M., Revol B., et al. High prevalence of spin was found in pharmacovigilance studies using disproportionality analyses to detect safety signals: a meta-epidemiological study // J Clin Epidemiol. 2021. Vol. 138. P. 73–79. DOI: 10.1016/j.jclinepi.2021.06.022

[21] Glagolev SV, Gorelov KV, Chizhova DA. Russian pharmacovigilance in a newly regulated environment: two-year results and prospects. Remedium. 2019;(3):6–14. (In Russ.). DOI: 10.21518/1561-5936-2019-3-8-14

[22] Глаголев С.В., Горелов К.В., Чижова Д.А. Российский фармаконадзор в условиях нового регулирования — итоги двух лет и перспективы // Ремедиум. 2019. № 3. С. 6–14. DOI: 10.21518/1561-5936-2019-3-8-14

[23] Reumerman M, Tichelaar J, Piersma B, et al. Urgent need to modernize pharmacovigilance education in healthcare curricula: review of the literature. Eur J Clin Pharmacol. 2018;74(10): 1235–1248. DOI: 10.1007/s00228-018-2500-y

[24] Reumerman M., Tichelaar J., Piersma B., et al. Urgent need to modernize pharmacovigilance education in healthcare curricula: review of the literature // Eur J Clin Pharmacol. 2018. Vol. 74. No. 10. P. 1235–1248. DOI: 10.1007/s00228-018-2500-y

[25] Zhuravleva MV, Romanov BK, Gorodetskaya GI, et al. Topical Issues of Drug Safety, Possibilities of Improving of Pharmacovigilance. Safety and Risk of Pharmacotherapy. 2019;7(3):109–119. (In Russ.).. DOI: 10.30895/2312-7821-2019-7-3-109-119

[26] Журавлева М.В., Романов Б.К., Городецкая Г.И., и др. Актуальные вопросы безопасности лекарственных средств, возможности совершенствования системы фармаконадзора // Безопасность и риск фармакотерапии. 2019. Т. 7, № 3. С. 109–119. DOI: 10.30895/2312-7821-2019-7-3-109-119

[27] Hartman J, Härmark L, van Puijenbroek E. A global view of undergraduate education in pharmacovigilance. Eur J Clin Pharmacol. 2017;73(7):891–899. DOI: 10.1007/s00228-017-2237-z

[28] Hartman J., Härmark L., van Puijenbroek E. A global view of undergraduate education in pharmacovigilance // Eur J Clin Pharmacol. 2017. Vol. 73. No. 7. P. 891–899. DOI: 10.1007/s00228-017-2237-z

[29] Matveev AV, Krasheninnikov AE, Matveeva EA, Romanov BK. Differences between the European and Eurasian Good Pharmacovigilance Practices. Safety and Risk of Pharmacotherapy. 2021;9(2):75–84. (In Russ.). DOI: 10.30895/2312-7821-2021-9-2-75-84

[30] Матвеев А.В., Крашенинников А.Е., Матвеева Е.А., Романов Б.К. Различия европейских и евразийских правил надлежащей практики фармаконадзора // Безопасность и риск фармакотерапии. 2021. Т. 9, № 2. С. 75–84. DOI: 10.30895/2312-7821-2021-9-2-75-84

Funding

Минздрав России(056-00005-21-02)

RIGHTS & PERMISSIONS

Taube A.A., Evko I.Y., Sinitova S.V., Krasheninnikov A.E., Zhuravleva M.V., Romanov B.K., Alyautdin R.N.